国产“减肥药”越来越便宜？乐普医疗子公司海外授权新药物潜在总交易额创同类新低

Core Viewpoint - The article discusses the overseas licensing deal of MWN105 injection by Lepu Medical, highlighting its lower price compared to similar GLP-1 drugs and its potential in the market [1][3]. Company Summary - Lepu Medical's subsidiary, Shanghai Minwei Biotechnology, licensed the overseas rights of MWN105 injection to Danish company Sidera, receiving 9.99% equity in Sidera and a total of $350 million in upfront and milestone payments [1][2]. - The MWN105 injection is a triple receptor agonist (GLP-1/GIP/FGF21) and is the first of its kind globally, with clinical trials for obesity and type 2 diabetes set to begin in China [2][5]. - The licensing agreement includes a combination of equity, milestone payments, and sales royalties, indicating a deep partnership between Minwei and Sidera [2][3]. Industry Summary - The GLP-1 drug market is becoming increasingly competitive, with many Chinese companies actively developing various GLP-1 products, including single, dual, and triple receptor agonists [5]. - The licensing price for MWN105 is significantly lower than similar drugs, setting a new low for domestic products entering overseas markets [5]. - The global market growth for GLP-1 drugs is slowing, with recent adjustments in sales forecasts from major companies like Novo Nordisk, indicating increased competition and high discontinuation rates among patients [5][6].